Recent Updates — CYBN

Co-founders Eric So and Paul Glavine have stepped down from their executive and consulting positions at Helus Pharma, effective October 26, 2026. Mr. So served as President and Executive Chairman, while Mr. Glavine was Chief Growth Officer. Both will remain on the Board of Directors, with Mr. So named Chairman Emeritus. The Board appointed Mark Lawson as independent Chair of the Board. Helus Pharma is a clinical-stage pharmaceutical company developing novel serotonergic agonists for mental health conditions.

Co-founders Eric So and Paul Glavine have stepped down from their respective executive and consulting positions at Helus Pharma Inc., though they will continue to serve on the Board of Directors. Mr. So previously served as President and Executive Chairman, while Mr. Glavine was Chief Growth Officer. The board appointed Mark Lawson, a private equity and investment banking executive who has served on the board since November 2020, as independent Chair effective immediately. Mr. So received the honorary title of Chairman Emeritus. Helus Pharma is a clinical-stage pharmaceutical company developing novel serotonergic agonists for mental health conditions.

Helus Pharma provided updates on its clinical pipeline during an investor presentation held on October 21, 2026. The company confirmed that topline data from the APPROACH Phase 3 study of HLP003 for major depressive disorder is on track for a Q4 2026 readout. Additionally, the HLP004 program for generalized anxiety disorder will initiate a Phase 2 monotherapy study in Q1 2027, enrolling approximately 144 participants. Helus Pharma operates as a clinical-stage pharmaceutical company developing novel serotonergic agonists for mental health conditions.

Helus Pharma Inc. announced the appointment of Dr. Suresh Durgam to its Board of Directors. Dr. Durgam previously served on the company's Scientific Advisory Board and brings over two decades of experience in CNS drug development, regulatory strategy, and medical affairs. Most recently, he was Executive Vice President and Chief Medical Officer at Intra-Cellular Therapies, where he helped secure FDA approvals for CAPLYTA across multiple indications before the company's acquisition by Johnson & Johnson. His appointment is subject to approval by Cboe Canada. Helus Pharma Inc. is a clinical-stage pharmaceutical company developing novel serotonergic agonists for mental health conditions.